The University of Texas MD Anderson Cancer Center?and?Schr?dinger, Inc.?(Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a two-year strategic research collaboration focused on accelerating and optimizing the development of Schr?dinger?s WEE1 inhibitor program, an investigational therapeutic approach designed to target the WEE1 kinase.

?Through our collaboration with Schr?dinger, we aim to identify clinically relevant patient populations that may benefit from WEE1 inhibition and to advance innovative targeted therapies that can improve their lives.?

Tweet this

The collaboration brings together the translational research and drug development expertise of MD Anderson?s Therapeutics Discovery division with Schr?dinger?s expertise and drug development program for WEE1 inhibitors. The goal of the collaboration is to accelerate and optimize the clinical development path for Schr?dinger?s WEE1 program through molecular biomarker-driven tumor type prioritization and patient stratification and to validate biomarkers to predict response or resistance to a WEE1 inhibitor. The joint team will seek to prioritize clinical studies of a WEE1 inhibitor as a single agent in selected cancer indications and in rational combinations for defined clinical subpopulations. ?We are excited to work with MD Anderson?s researchers to speed the development of our WEE1 program and potentially advance a new therapeutic option for patients,? said Karen Akinsanya, Ph.D., executive vice president, chief biomedical scientist and head of discovery research and development at Schr?dinger. ?We have identified multiple highly selective WEE1 inhibitors with desirable drug-like properties that show strong pharmacodynamic responses and anti-tumor activity in preclinical models. We believe this profile may position our compounds as ideal candidates for applications both as monotherapy and as combination therapy partners.? Under the preclinical collaboration agreement, Schr?dinger will join forces with researchers in MD Anderson's?Translational Research to AdvanCe Therapeutics and Innovation in ONcology (TRACTION) platform, which leads cutting-edge translational biology research to rapidly position new therapies for clinical trials. TRACTION is a core component of MD Anderson?s Therapeutics Discovery division, an integrated team of clinicians, researchers and drug development experts working to advance impactful therapies that address patient needs. ?Targeting WEE1, a critical gatekeeper of the cell cycle, is showing promise as a therapeutic strategy for treating certain cancers with select genetic alterations,? said?Timothy Heffernan, Ph.D., executive director of TRACTION. ?Through our collaboration with Schr?dinger, we aim to identify clinically relevant patient populations that may benefit from WEE1 inhibition and to advance innovative targeted therapies that can improve their lives.? MD Anderson and Schr?dinger will jointly pursue translational studies, and Schr?dinger will provide research support funding. As part of the agreement, MD Anderson is eligible to receive certain payments based on the future development and commercialization of Schr?dinger?s WEE1 inhibitor compounds. Schr?dinger will have sole responsibility for the development, manufacture and commercialization of all compounds and products, and sole rights to all novel intellectual property that arises from this collaboration. WEE1 is a gatekeeper checkpoint kinase that prevents progression through the cell cycle, allowing time for DNA repair to occur before cell division takes place. Thus, inhibition of WEE1 allows for accumulation of DNA damage, triggering DNA breakage and apoptosis in tumor cells. Schr?dinger is developing tight-binding, selective WEE1 inhibitors with optimized physicochemical properties designed to be well suited for combinations with other DNA damage response therapies for the treatment of a broad range of solid tumors. About MD Anderson The University of Texas MD Anderson Cancer Center?in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution's sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is No.1 for cancer in U.S. News & World Report's "Best Hospitals" rankings. It has been named one of the nation's top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672). About Schr?dinger Schr?dinger is transforming the way therapeutics and materials are discovered. Schr?dinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schr?dinger?s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs. Founded in 1990, Schr?dinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit?www.schrodinger.com?and follow us on?LinkedIn?and?Twitter. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding our expectations about the speed and capacity of our computational platform, the potential of our collaboration with MD Anderson to accelerate the development of our WEE1 inhibitor program, the clinical potential and favorable properties of our WEE1 inhibitors, as well as the potential for our WEE1 inhibitors to be used as a single agent and in combination with other therapies, and the risk that we may not realize the expected benefits of the collaboration. Statements including words such as ?anticipate,? ?believe,? ?contemplate,? ?continue,? ?could,? ?estimate,? ?expect,? ?intend,? ?may,? ?might,? ?plan,? ?potential,? ?predict,? ?project,? ?should,? ?target,? ?will,? ?would? and statements in the future tense are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including our reliance upon third-party providers of cloud-based infrastructure to host our software solutions, our reliance on third party contract research organizations to assist in the discovery of development candidates, our reliance on MD Anderson to perform its obligations under the collaboration, including assisting in designing translational studies, the uncertainties inherent in drug development and commercialization, uncertainties associated with the regulatory review of clinical trials and applications for marketing approvals, the potential impact of the COVID-19 pandemic on our operations or the operations of third parties we rely on, as well as the other risks and uncertainties identified under the caption "Risk Factors" and elsewhere in our Securities and Exchange Commission filings and reports, including the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2021, as well as future filings and reports by us. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.